CTRI/2019/11/022127Other未知
A multicentric, open label, multiple dose, balanced, randomized, two-treatment, two-period, twosequence,full replicate, cross over study to evaluate bioequivalence of Etoposide Capsules 100 mg(Intas Pharmaceuticals Ltd., India) with Vepesid Soft Capsules 100 mg (Bristol-Myers Squibb S.r.lItaly) in patients with metastatic small cell lung cancer (SCLC) under fasting conditions.
试验速览
- 阶段
- 未知
- 状态
- Other
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Male and female patients between 18 and 65 years of age (both inclusive).
- •2. Patients with confirmed metastatic small cell lung cancer.
- •3. Patients who are already receiving etoposide and expected to receive at least two additional cycles at the same dose.
- •4. Patients between BSA of 1.26 m2 and 2.00 m2 (both inclusive) who have received etoposide in the dose of 200mg once daily for 5 days and cisplatin 25mg/m2 administered on days 1, 2 and 3 in the previous cycle and are expected to receive same (200mg once daily (days 1-5) for etoposide and 25mg/m2 daily (days 1-3) for cisplatin) doses for the next 2 consecutive cycles (i.e. during the course of the study)
- •5. Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- •6. Patient with adequate bone marrow (without supplemental blood products/haematopoietic growth factors), renal and hepatic function.
- •7. Adequate Cardiac function (left ventricular ejection fraction [LVEF] >=50%)
- •8. Patient should have recovered from any toxic effects of previous chemotherapy as judged by the Investigator
- •9. Patients with life expectancy of at least 3 months.
- •10. Able to comply with study requirement in opinion of Principal Investigator.
- •11. Patient able to give written informed consent for participation in the trial.
- •12. In case of female patient the serum pregnancy test at screening visit and urine
- •pregnancy test at day 1 must be negative.
- •13. In case of Male patients: Either partner or patient must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 6 months after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
- •14. Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral,
- •transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with
- •spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] sexual partner) for at least 4 weeks prior to study drug administration, during study and up to 6 months after the last dose of study drug. Cessation of birth control after this point should be discussed with a
- •responsible physician.
排除标准
- •1. Patients who have demonstrated a previous hypersensitivity to the IMP or any component of the formulation.
- •2. Patients who have received more than 4 cycles of etoposide in the past.
- •3. Patients with history of Tumour lysis syndrome
- •4. Patients with ongoing significant active infection.
- •5. History of prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a 3-year disease-free interval.
- •6. Creatinine clearance less than or equal to 50 mL/min
- •7. Patients with Daily dosing requirement greater than 200 mg etoposide.
- •8. Pregnant or breast-feeding female patients.
- •9. History of drug/alcohol addiction in past one year.
- •10. Known symptomatic brain metastasis
- •11. Patients receiving or expected to receive radiotherapy along with chemotherapy.
- •12. A positive hepatitis screen including hepatitis B surface antigen and HCV antibodies, or HIV infection.
- •13. Patients received any other chemotherapy, surgery or radiotherapy within 4 weeks before randomization or who have not recovered from side effects of such therapy.
- •14. Uncontrolled hypertension. Patients with history of hypertension must be well controlled
- •(<=140/90) on a stable regimen of anti-hypertensive therapy.
- •15. Concomitant use of CYP3A4 inhibitors.
- •16. Patients with massive pleural effusion, ascites and/or pericardial effusion
- •17. The receipt of an investigational medicinal product or participation in other drug research study within a period of 60 days prior to the first dose of investigational medicinal Product for the current study.
- •18. Clinically significant cardiac, neurological, psychiatric condition or any other condition that, in the investigator judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- •19. Abnormal baseline findings considered by the investigator to indicate conditions that might affect study endpoints or patient safety.
- •20. Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product for the current study.
研究者
相似试验
已完成
1 期
To evaluate safety and amount of Cabazitaxel lipid suspension in blood in comparison with JEVTANA® (Cabazitaxel) injection in patients with advanced solid cancerCTRI/2015/06/005948Intas Pharmaceuticals Ltd33
已完成
不适用
Bioequivalence study of asenapine sublingual tablets in patientsCTRI/2013/11/004152Amneal Pharmaceuticals LLC USA48
进行中（未招募）
1 期
Comparative pharmacokinetics study (study to know the amount of study drug (cyclophosphamide) in your blood at specified time points – to understand what body does to this study drug) of two products of cyclophosphamide powder for oral solution and Cyclophosphamide Tablets 50 mg in adult patients with breast cancerAdult female patients with breast cancer.MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-004897-77-Outside-EU/EEAIntas Pharmaceuticals Ltd.
已完成
不适用
A study of cyclophosphamide powder for oral solution in adult patients with breast cancer.CTRI/2021/11/037948Intas Pharmaceuticals LtdIndia
已完成
不适用
Bioequivalence study of Olaparib Tablets 150 mgCTRI/2023/01/048868Cipla Limited44